How VTE Prophylaxis Decisions Are Risk Stratified in the Hospital

Venous thromboembolism prophylaxis in the hospital is a decision about two competing harms, not one. Clinicians estimate how likely a medical inpatient is to form a clot if left unprotected, then estimate how likely that same patient is to bleed if given an anticoagulant, and they act on whichever risk dominates. Validated tools such as the Padua Prediction Score and the IMPROVE models put numbers on each side of that trade-off, and the American Society of Hematology 2018 guideline panel translated the balance into concrete, graded recommendations. The core logic is plain: prophylaxis helps only when the clot it prevents is more probable, and more dangerous, than the bleed it might cause.

Why hospitals stratify at all

A large share of hospital-associated venous thromboembolism arises in medical inpatients and other non-surgical groups rather than after an operation, which is why the ASH 2018 guideline devotes a full document to preventing it in them. Yet most individual medical patients will never clot, and pharmacologic prophylaxis is not free: heparins carry a real bleeding cost. Giving a blood thinner to everyone would expose a large low-risk majority to harm in order to help a small high-risk minority. Risk stratification exists to find that minority before treating it.

What the clot-risk models measure

The Padua Prediction Score

The Padua Prediction Score, derived by Barbar and colleagues in a 2010 prospective cohort published in the Journal of Thrombosis and Haemostasis, assigns points to eleven factors. Active cancer, prior VTE, reduced mobility, and known thrombophilia each carry three points; recent trauma or surgery carries two; and age of seventy or older, heart or respiratory failure, recent stroke or myocardial infarction, acute infection or rheumatologic disorder, obesity, and ongoing hormonal treatment each add one. A total of four or more marks a patient as high risk.

The numbers behind the cutoff are what make it useful. In the original cohort, high-risk patients who received no prophylaxis developed symptomatic VTE about eleven percent of the time, compared with roughly two percent among high-risk patients who were treated, and about 0.3 percent among low-risk patients. A single score separated a group with a meaningful clot rate from a group in whom prophylaxis would mostly add risk without benefit.

The IMPROVE models and the bleeding side

Padua speaks only to clot risk. The other half of the decision comes from the IMPROVE program, the International Medical Prevention Registry on Venous Thromboembolism, which produced two complementary tools. The IMPROVE VTE score weights factors such as prior VTE, known thrombophilia, lower-limb paralysis, active cancer, prolonged immobilization, intensive care admission, and older age to estimate clotting risk. Its companion, the IMPROVE bleeding risk score, estimates the competing danger, drawing on predictors including active gastroduodenal ulcer, recent bleeding, low platelet count, advanced age, hepatic and severe renal impairment, intensive care stay, central venous catheters, and active cancer. A bleeding score at or above a defined threshold flags a patient in whom anticoagulant prophylaxis is more likely to cause harm than to help.

Pairing the two scores is the point. A 2024 analysis by Djulbegovic and colleagues in Blood Advances showed how the IMPROVE bleeding and VTE models can be combined into a simple sequential decision tree: check bleeding risk first, withhold pharmacologic prophylaxis when it is high, and reserve anticoagulation for patients whose clot risk is elevated and whose bleeding risk is acceptable. That sequence encodes the long-standing clinical instinct to avoid causing harm before chasing benefit.

How a panel turned the trade-off into recommendations

The ASH 2018 guideline, led by Schünemann and a panel convened with the McMaster GRADE Centre, took this two-sided assessment and issued graded recommendations rather than a single rule. For acutely and critically ill medical inpatients, the panel suggested pharmacologic prophylaxis over none, reflecting a net benefit when clot risk outweighs bleeding risk. When a drug is used, it favored low-molecular-weight heparin over unfractionated heparin, citing once-daily dosing and fewer complications. It preferred inpatient low-molecular-weight heparin over a direct oral anticoagulant continued after discharge, declining to endorse routine extended-duration prophylaxis.

The trade-off shows most clearly at the extremes. For patients at high bleeding risk who still need protection, the panel preferred mechanical prophylaxis, such as pneumatic compression, over anticoagulant drugs. For patients at high clot risk but acceptable bleeding risk, it preferred the drug over mechanical measures. And it judged combined mechanical-plus-pharmacologic prophylaxis unnecessary for most medical inpatients, since the added burden was not matched by clear added benefit. Most of these are conditional recommendations under GRADE, a deliberate signal that the balance is close and sensitive to the individual patient.

Where judgment still lives

Two cautions matter. First, a risk model is a starting estimate, not a verdict; the ASH panel framed decisions around VTE and bleeding risk without crowning any single score as mandatory, and a tool derived in one population can perform differently in another. Second, a score captures the average, while the patient in front of a clinician may sit at the edges of it. The value of Padua and IMPROVE is that they force both halves of the question, clot and bleed, to be asked out loud and weighed against each other, rather than letting one side go unexamined.

This article is educational and not medical advice.